問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

1738Cases

2017-07-15 - 2022-06-30

Phase III

Completed
An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract.

  • Condition/Disease

    Urinary Tract Cancer

  • Test Drug

    TECENTRIQ (Atezolizumab)

Participate Sites
2Sites

Terminated2Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-04-02 - 2023-12-06

Phase II

Completed
An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa (RO6874281), an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors

  • Condition/Disease

    Advanced and/or Metastatic Solid Tumors

  • Test Drug

    RO6874281、ATEZOLIZUMAB

Participate Sites
2Sites

Terminated2Sites

2018-03-16 - 2024-12-05

Phase III

Completed
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  • Condition/Disease

    High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    TECENTRIQ (Atezolizumab)

Participate Sites
5Sites

Terminated5Sites

2016-06-01 - 2024-06-28

Phase III

Completed
A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY

  • Condition/Disease

    LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  • Test Drug

    TECENTRIQ (Atezolizumab)

Participate Sites
7Sites

Terminated6Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2005-12-01 - 2006-12-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-10-01 - 2017-06-30

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2007-06-01 - 2013-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-10-01 - 2025-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2025-10-15 - 2032-12-31

Phase III

Not yet recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

  • Condition/Disease

    Parkinson's Disease

  • Test Drug

    injections

Participate Sites
5Sites

Recruiting5Sites

2023-04-01 - 2030-12-31

Phase III

Active
A PHASE III, MULTICENTER, RANDOMIZED, OPEN LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS FULVESTRANT VERSUS ALPELISIB PLUS FULVESTRANT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE, PIK3CA MUTATED LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO PROGRESSED DURING OR AFTER CDK4/6 INHIBITOR AND ENDOCRINE COMBINATION THERAPY

  • Condition/Disease

    Patients with locally advanced or metastatic breast cancer who have PIK3CA mutations, are hormone receptor-positive, and HER2-negative

  • Test Drug

    GDC-0077(Inavolisib)Alpelisib(Piqray)Fulvestrant (Faslodex)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

1 2 3 4 5 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB